ClinicalTrials.gg
CompletedNCT00235885STEREOUpdated Aug 29, 2007

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

A Phase 3 interventional study of adalimumab in Psoriatic Arthritis, sponsored by Abbott. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-08-29.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
445
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies testing adalimumab in Arthritis, Psoriatic — 5 open to participants now, 5 under way, 2 of them phase 3. Adalimumab · Arthritis, Psoriatic.

Enrollment
Largest of 13
445 · median 108
Started
2005
the only one that year
Phase 3
5 of 13
2 open now
Registered
1st of 13
by date
Lead sponsor
2 of 13
Abbott

Among the 13 studies testing adalimumab in Arthritis, Psoriatic, this one has the largest enrollment, is the only one that started in 2005, is one of 5 in phase 3, and was the 1st registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 13 studies testing adalimumab in Arthritis, Psoriatic are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Arthritis, Psoriatic studies recruiting now, 52 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing adalimumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other TNF therapies

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriatic Arthritis
  • adalimumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females > 18 years of age
  • Active PsA with > 3 tender and > 3 swollen joints despite standard therapy
  • Unsatisfactory response or intolerance to at least one prior or ongoing DMARD (study enrollment must be in accordance with current national guidelines for treatment of PsA with TNF inhibitors)
  • A negative serum pregnancy test (serum HCG) for women of prior to the start of treatment.
  • Use of a reliable method of by all female patients of childbearing potential
  • Able and willing to self-administer sc injections or have a suitable person to administer sc injections
  • Able and willing to give written and comply with the protocol

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any agent within 30 days or five half lives of the product, whichever is longer
  • Treatment within last 2 months with infliximab or within last 3 weeks with etanercept
  • Treatment within last 4 weeks with a combination of MTX and leflunomide
  • Treatment within last 4 weeks with a combination of cyclosporine with any other DMARD-Subject has received UVA phototherapy (including PUVA within 2 weeks prior to screening)
  • History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin or cervical dysplasia
  • History of or current active acute inflammatory joint disease of origin other than PsA
  • Comorbidities (uncontrolled diabetes, unstable ischemic heart disease, CHF, active IBD, stroke within 3 months, chronic leg ulcer and other condition which would put subject at risk by participation in the protocol
  • Positive serology for or C
  • History of positive status
  • Persistent or recurrent infections or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment
  • Females who are pregnant or breast-feeding
  • History of drug or alcohol abuse in the last year
  • Previous diagnosis or signs of central nervous system demyelinating diseases
  • History of tuberculosis, histoplasmosis or listeriosis
  • Subjects with latent TB or having other risk factors for activation of latent TB who have not initiated a TB prophylaxis prior to the first adalimumab treatment .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
445 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Safety parameters

  2. PsARC

  3. ACR20

  4. Physician Global Assessment for Psoriasis and Psoriasis Target Lesion Assessment

  5. Patient reported outcomes

Secondary outcomes

  1. No differentiation will be made between primary and secondary efficacy variables.

07

Study locations

1 site
  • Global Medical Information - Abbott
    Abbott Park, Illinois 60064, United States
08

References and documents

Publications

  • Van den Bosch F, Kavanaugh A, Kron M, Kupper H, Mease PJ. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations. J Rheumatol. 2015 Jun;42(6):952-9. doi: 10.3899/jrheum.140312. Epub 2015 Apr 1. PubMed 25834212 ↗
  • Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16. PubMed 20553600 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00235885
Lead sponsor
Abbott
First posted
Oct 12, 2005
Start date
Jul 2005
Last update
Aug 29, 2007

Study contacts

Beverly Paperiello
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion